Biogen’s Recent Development and Market Metrics

Biogen has announced the completion of its Phase 3 trial for Dapirolizumab Pegol in the treatment of Systemic Lupus Erythematosus. The trial has met its primary objective.

Trial Results and Stock Performance

• The trial’s primary objective was met, marking a significant milestone in the development of Dapirolizumab Pegol.
• Over the past year, Biogen’s stock price has fluctuated between $238 and $110.04.
• As of the last close, Biogen’s stock price stood at $131.04.

Market Valuation Metrics

• Price-to-earnings ratio: 13.06
• Price-to-book ratio: 1.14
• These metrics provide a snapshot of Biogen’s current market valuation.